<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:mp ids='MP_0002038'>Carcinomas</z:mp> of the Vaterian system are rare and presumably arise from pre-existing <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>According to the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell (<z:chebi fb="11" ids="17437,53115">CSC</z:chebi>) hypothesis, only a small subset of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells has the ability to initiate and develop <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, CD44, CD133, CD166 and EpCAM have been proposed to represent <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> marker proteins and their expression has been shown to correlate with patient survival </plain></SENT>
<SENT sid="3" pm="."><plain>AIMS: To evaluate a potential role of these <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> proteins in <z:e sem="disease" ids="C0345916" disease_type="Neoplastic Process" abbrv="">tumors of the ampulla of Vater</z:e>, we investigated their expression in 175 <z:mp ids='MP_0002038'>carcinoma</z:mp>, 111 <z:mpath ids='MPATH_270'>adenoma</z:mpath> and 152 <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa specimens arranged in a Tissue Microarray format </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIALS AND METHODS: Membranous immunoreactivity for each protein marker was scored semi-quantitatively by evaluating the number of positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells over the total number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>Median protein expression levels were used as cut-off scores to define protein marker positivity </plain></SENT>
<SENT sid="6" pm="."><plain>Clinical data including survival time were obtained by retrospective analysis of medical records, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> registries or direct contact </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The expression of <z:hpo ids='HP_0000001'>all</z:hpo> evaluated marker proteins differed significantly between <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:mp ids='MP_0002038'>carcinoma</z:mp> samples </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> markers, we found a tendency towards more constant expression from <z:mpath ids='MPATH_458'>normal</z:mpath> to neoplastic tissue </plain></SENT>
<SENT sid="9" pm="."><plain>EpCAM expression was significantly correlated with better patient survival </plain></SENT>
<SENT sid="10" pm="."><plain>The increased expression of CD44s, CD166 and CD133 from <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa samples to <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:mp ids='MP_0002038'>carcinoma</z:mp> was linked to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>However, there was no statistically significant correlation with survival </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Our findings indicate, that in ampullary <z:mp ids='MP_0002038'>carcinomas</z:mp>, loss of expression of EpCAM may be linked to a more aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> phenotype </plain></SENT>
</text></document>